Tourette Syndrome (TS) is a neurological disorder characterized by involuntary, repetitive movements and vocalizations called tics. It is estimated to affect 1 in 160 children and adolescents worldwide. Symptoms of TS can range from mild to severe and can include motor tics such as eye blinking, facial grimacing, and shoulder shrugging, as well as vocal tics such as throat clearing, sniffing, and grunting. Treatment for TS typically involves a combination of medications, psychotherapy, and lifestyle modifications.
The Tourette Syndrome market within the context of Neurology is a growing field of research and development. Pharmaceutical companies are investing in the development of new treatments for TS, such as deep brain stimulation and gene therapy. Additionally, there is an increasing focus on developing non-pharmacological treatments, such as cognitive behavioral therapy and mindfulness-based interventions.
Some companies in the Tourette Syndrome market include AbbVie, Inc., GlaxoSmithKline, Pfizer, Inc., and Novartis AG. Show Less Read more
